RxDoctor Payments Data

Kent Posey, MD

Neurology · Moultrie, GANPI 1689802258

Payments from drug & device makers

$22,149in general payments, 2019–2025

Across 366 payments — averaging $60.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Biohaven Pharmaceutical Holding Company Ltd.$3K
  • Biohaven Pharmaceuticals, Inc.$2K
  • Medtronic$1K
  • Biogen$711
  • Novartis$526
  • plus $4K from 43 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$14,10064%
  • Travel & lodging$1,8198%
  • Food & beverage$5,72726%
  • Education$2031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,149 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$223,645
Medicare patients
713
Services billed
3,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate104$913,210
BotoxOnabotulinumtoxina144$243,915
AustedoDeutetrabenazine16$231,897
Kesimpta PenOfatumumab21$206,904
ApokynApomorphine Hcl11$203,386
Austedo XrDeutetrabenazine17$190,144
NuplazidPimavanserin Tartrate28$127,682
Nurtec OdtRimegepant Sulfate73$123,323
Avonex Pen (4 Pack)Interferon Beta-1a14$122,112
MayzentSiponimod12$112,935
Aimovig AutoinjectorErenumab-Aooe126$106,116
VumerityDiroximel Fumarate12$103,600
EpidiolexCannabidiol (Cbd)14$57,453
UbrelvyUbrogepant41$49,603
GlatopaGlatiramer Acetate19$43,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$118$913,210104 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$361$422,04133 claims
AbbVieBotox, Ubrelvy, Qulipta$11,307$325,903205 claims
Acadia Pharmaceuticals IncNuplazid$14$127,68228 claims
PfizerNurtec Odt$172$123,32373 claims
NovartisMayzent$526$112,93512 claims
BiogenVumerity$711$103,60012 claims
Kyowa Kirin, Inc.Nourianz$99$42,88217 claims
MDD US Operations, LLCGocovri$99$42,73120 claims
UCB, Inc.Briviact, Neupro$327$40,28933 claims
Otsuka America Pharmaceutical, Inc.Rexulti$59$28,90719 claims
Sunovion Pharmaceuticals Inc.Aptiom$126$16,16212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.

Other neurology in Moultrie

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →